WD-1603 ( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	5

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05128175 (ClinicalTrials.gov)	October 29, 2021	27/10/2021	Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and F ...	An Open-label, Balanced, Randomized, Five-treatment, Five-period, Five-sequence, Multiple Oral Dose, ...	Parkinson Disease	Drug: WD-1603 Carbidopa-Levodopa Extended-Release Tablets	Shanghai WD Pharmaceutical Co., Ltd.	NULL	Recruiting	18 Years	45 Years	All	15	Phase 1	India
2	NCT05036473 (ClinicalTrials.gov)	October 12, 2021	10/8/2021	A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With P ...	A Phase II Randomized, Parallel, Double-blind, Placebo-controlled, Multi-center Clinical Trial of th ...	Parkinson Disease	Drug: WD-1603 Carbidopa-Levodopa Extended-Release Tablets;Drug: Placebo	Shanghai WD Pharmaceutical Co., Ltd.	NULL	Recruiting	30 Years	75 Years	All	40	Phase 2	China
3	NCT04591535 (ClinicalTrials.gov)	September 28, 2020	11/9/2020	PK Study of WD-1603 in Healthy Subjects	An Open Label, Balanced, Randomised, Four-treatment, Four-period, Four-sequence, Single Oral Dose, C ...	Parkinson Disease	Drug: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS	Hong Kong WD Pharmaceutical Co., Limited	NULL	Recruiting	18 Years	45 Years	All	8	Phase 1	India
4	NCT04553978 (ClinicalTrials.gov)	September 18, 2020	13/9/2020	A Single Oral Dose, Crossover Comparative PK Study of WD-1603in Healthy Subjects Under Fasting Condi ...	An Open Label, Balanced, Randomised, 2-treatment, 2-period, 2-sequence, Single Oral Dose, Corssover ...	Parkinson Disease	Drug: WD-1603	Hong Kong WD Pharmaceutical Co., Limited	NULL	Not yet recruiting	18 Years	45 Years	All	8	Phase 1	NULL
5	NCT04513340 (ClinicalTrials.gov)	August 13, 2020	12/8/2020	WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects	AN OPEN LABEL, BALANCED, RANDOMISED, FOUR-TREATMENT, FOUR-PERIOD, FOUR-SEQUENCE, SINGLE INTRA-ORAL A ...	Parkinson Disease	Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS	Hong Kong WD Pharmaceutical Co., Limited	NULL	Recruiting	18 Years	45 Years	All	8	Phase 1	India

First Previous1Next Last